CN Bio Raises $21 Million USD in First Close of Series B Investment Round
CN Bio and Altis Biosystems Partner to Develop Next-generation Human Gut/Liver in vitro model for Advanced ADME Studies
CN Bio PhysioMimix Organ-on-a-Chip Data Supports Inipharm’s INI-822
CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards. The award recognises the ongoing success of the Company’s collaboration with the U.S. Food and Drug Administration (FDA), aimed at advancing OOC adoption through evaluation of its PhysioMimix® OOC range of MPS across a series of applications in drug discovery and development.
CN Bio Appoints Deepak Singh as Vice President of Sales and Marketing
Tech was created to overcome adoption obstacles currently reducing the use of predictive human liver models
The FDA Further Expands Collaboration With CN Bio to Evaluate the PhysioMimix Multi-Organ Microphysiological System
CN Bio appoints Dr Paul Brooks as Chief Executive Officer
Demand from discovery labs for so-called organ-on-a-chip based testing is growing, according to CN Bio, which has doubled capacity at the bioengineering company’s testing facility.
CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the opening of new laboratory facilities at Cambridge Science Park, dedicated to its contract research services. The Company’s laboratory space has been doubled in response to the increasing market demand for OOC services as the technology gains traction within drug discovery and development programmes.